ArticleFrontiers in immunology2026
DEB-TACE-HAIC combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma: a multicenter retrospective study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TACE-HAIC combined with apatinib and camrelizumab for unresectable hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study.Frontiers in immunology · 2026Article
- Editorial: Checkpoint immunotherapy: reshaping the landscape of gastrointestinal cancer treatment, volume II.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with hepatic arterial infusion chemotherapy (HAIC), donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma (uHCC). Methods: This multicenter retrospective analysis enrolled patients with unresectable hepatocellular carcinoma (uHCC) from 4 Grade A tertiary hospitals in China, with data collected between December 2022 and December 2024. Patients were stratified into two groups based on their treatment modalities: the DEB-TACE-HAIC combined with donafenib and camrelizumab group (DHDC) and the DEB-TACE combined with donafenib and camrelizumab group (DDC). The modified Response Evaluation Criteria in Solid Tumors (mRECIST) was utilized to assess and compare the objective response rate (ORR) and disease control rate (DCR) between the two cohorts. Survival curves were generated using the Kaplan-Meier method, and differences in progression-free survival (PFS) and overall survival (OS) were analyzed by the Log-rank test. Additionally, the Cox proportional hazards regression model was employed to identify independent prognostic factors for PFS and OS. Results: A total of 122 patients were ultimately enrolled in this study, with 58 patients were enrolled in the DHDC group and 64 patients were enrolled in the DDC group. Baseline characteristics were well balanced between the two groups. The median follow-up duration was 18 months in the DHDC group and 14 months in the DDC group. Before inverse probability of treatment weighting (IPTW) adjustment, the DHDC group had higher ORR (74.1% vs. 51.6%, P = 0.010) and DCR (91.4% vs. 75.0%, P = 0.017) than the DDC group. These advantages remained after IPTW adjustment (ORR: 72.5% vs. 53.4%, P = 0.036; DCR: 90.7% vs. 75.3%, P = 0.033). Kaplan-Meier analysis showed that the DHDC group had longer median PFS (16 vs. 11 months, P < 0.001) and OS (28 vs. 18 months, P < 0.001) than the DDC group before IPTW adjustment; these differences remained after IPTW (PFS: 16 vs. 11 months, P < 0.001; OS: 28 vs. 19 months, P < 0.001).On multivariable Cox analysis, portal vein tumor thrombosis (PVTT) ( Conclusion: Among patients with uHCC, the DHDC quadruple regimen was associated with improved survival outcomes while maintaining an acceptable safety profile. These findings suggest that a treatment strategy incorporating DEB-TACE-HAIC in combination with targeted therapy and immunotherapy may represent a more effective therapeutic option for selected patients with uHCC, warranting further prospective investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.